过氧化物酶体增殖物激活受体
内分泌学
炎症
内科学
罗格列酮
医学
败血症
兴奋剂
β氧化
下调和上调
肿瘤坏死因子α
过氧化物酶体
过氧化物酶体增殖物激活受体δ
受体
生物
核受体
转录因子
生物化学
新陈代谢
基因
作者
Konstantinos Drosatos,Raffay S. Khan,Chad M. Trent,Hongfeng Jiang,Ni-Huiping Son,William S. Blaner,Shunichi Homma,Paul Christian Schulze,Ira J. Goldberg
标识
DOI:10.1161/circheartfailure.112.000177
摘要
BACKGROUND: Cardiac dysfunction with sepsis is associated with both inflammation and reduced fatty acid oxidation. We hypothesized that energy deprivation accounts for sepsis-related cardiac dysfunction. METHODS AND RESULTS: Escherichia coli lipopolysaccharide (LPS) administered to C57BL/6 mice (wild type) induced cardiac dysfunction and reduced fatty acid oxidation and mRNA levels of peroxisome proliferator-activated receptor (PPAR)-α and its downstream targets within 6-8 hours. Transgenic mice in which cardiomyocyte-specific expression of PPARγ is driven by the α-myosin heavy chain promoter (αMHC-PPARγ) were protected from LPS-induced cardiac dysfunction. Despite a reduction in PPARα, fatty acid oxidation and associated genes were not decreased in hearts of LPS-treated αMHC-PPARγ mice. LPS treatment, however, continued to induce inflammation-related genes, such as interleukin-1α, interleukin-1β, interleukin-6, and tumor necrosis factor-α in hearts of αMHC-PPARγ mice. Treatment of wild-type mice with LPS and the PPARγ agonist, rosiglitazone, but not the PPARα agonist (WY-14643), increased fatty acid oxidation, prevented LPS-mediated reduction of mitochondria, and treated cardiac dysfunction, as well as it improved survival, despite continued increases in the expression of cardiac inflammatory markers. CONCLUSIONS: Activation of PPARγ in LPS-treated mice prevented cardiac dysfunction and mortality, despite development of cardiac inflammation and PPARα downregulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI